BIIB vs ZBH
Biogen vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | BIIB | ZBH |
|---|
| AI Score |
67
|
70
|
| Price |
$208.02
|
$96.61
|
| P/E Ratio |
36.61×
|
23.38×
|
| ROE |
7.1%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
69.9%
|
| Debt / Equity |
0.44×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
56.7
|
58.9
|
| Beta |
0.158
|
0.468
|
| Expected Upside |
+5.2%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus ZBH.
ZBH leads by 3 points.
ZBH scores 70/100 (Buy) versus BIIB at 67/100 (Buy).
BIIB Committee View
80% agreement
5 analysts
The primary driver is news sentiment is positive (+0.42 across 47 articles, 14d). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.